Global Abortion And Marketing Challenges For Misoprostol (Cytotec): The Future Of Womens Health by Antommattei, Osvaldo et al.
International Business & Economics Research Journal – January 2009 Volume 8, Number 1 
105 
Global Abortion And Marketing Challenges 
For Misoprostol (Cytotec):  The Future Of 
Women’s Health 
Osvaldo Antommattei, Nova Southeastern University, USA 
Nile M. Khanfar, Nova Southeastern University, USA 
Bahaudin G. Mujtaba, Nova Southeastern University, USA 
 
 
ABSTRACT 
 
This paper provides an overview of the controversial drug Misoprostol (Cytotec) and its 
importance for women’s health worldwide while presenting global challenges related to abortion. 
Furthermore, this paper discusses marketing challenges and opportunities that exist in today’s 
global marketplace for this drug. Misoprostol is an approved drug utilized to prevent stomach 
ulcers caused by non-steroidal anti-inflammatory drugs (NSAID’s), but it also has an “off label” 
use as an abortion pill for which it is being used today. Worldwide implications are vast and 
Misoprostol presents a future challenge for clinical studies and marketing professionals. 
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BACKGROUND AND IMPORTANCE OF THE DRUG 
 
he pharmaceutical company that produces Misoprostol does not encourage its “off label” use as an 
abortion pill; therefore, they have not marketed the drug for the past several years. However, many 
countries that do not follow FDA regulations use Misoprostol as an abortion pill. There are 
worldwide implications for the use of this drug because in many countries it may benefit women who otherwise 
would have severe complications or even die during an abortion.  
 
In 1988, Misoprostol (Cytotec) was approved and sold by Monsanto Co., a success for Searle 
Pharmaceutical, now distributed by Pfizer Pharmaceuticals, to prevent stomach ulcers caused by NSAID drugs, such 
as aspirin, ibuprofen, piroxicam, and naproxen.
1  
This cyto-protective drug acts by replacing prostaglandins in the 
stomach and also has an “off-label” or unapproved use as an abortion pill.  Searle never intended Misoprostol 
(Cytotec) to be used as an abortion pill, nor has it been approved in Britain or France with or without RU-486. The 
drug’s label has a contraindication in women of childbearing potential.2   The controversy of this drug is that since 
abortion was legalized in 1973, abortion drugs containing a prostaglandin are used to terminate early pregnancies.  
In Europe, women use Misoprostol (Cytotec) for two days to bring about a complete abortion. Misoprostol (Cytotec) 
is used in France for this purpose (as an “off- label” drug), but the company that manufactures Misoprostol (Cytotec) 
never officially intended to seek approval for its use. Nevertheless, France, which has no FDA regulation but is 
considered one of the top leading countries in pharmaceutical development, requires the selling of Misoprostol 
(Cytotec) as an abortion drug.
3 
 
 Some pharmaceutical companies are looking for ways to confer scientific literature on “off-label” or 
unapproved drug use. Accordingly, in other countries many physicians already are permitted to prescribe drugs for 
unapproved uses.
4  
 It should be noted that the FDA regulates the educational value of information when direct-to-
consumer advertising is conducted.  Misoprostol was never intended for use as an abortion pill in the U.S.; however, 
it was established by the FDA as a potential risk for its unproven studies on abortion. This is why drugs with FDA 
approval may be marketed to consumers. Evidence has shown that widespread use of new drugs may be 
counterproductive in the absence of solid evidence and studies of an advantage over existing conventional 
alternatives.
5 
Present studies on the use of Misoprostol have been reported, but there is still much research to be 
T 
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done before direct-to-consumer marketing can ever take place in the United States. Consequently, a percentage of all 
drugs are withdrawn from the market for health-related reasons. 
 
LITERATURE REVIEW OF STUDIES 
 
Since the pharmaceutical industry has looked the other way in U. S. markets in developing and registration 
of Misoprostol for pregnancy failures, studies have been limited by a small number of subjects.  Following are 
results that demonstrate the efficacy, safety and acceptability of treatment with Misoprostol. 
 
In 2005, a study of 800μg of Misoprostol (Cytotec) was given vaginally to induce early pregnancy failure, 
with a repeated dose after 48 hours when it was necessary.  A population of 652 women participated in this study. 
Of this population, 491 were assigned to Misoprostol (Cytotec) with complete success and 161 (16%) were assigned 
to vacuum aspiration when Misoprostol was not effective in the randomized trial.
6 
 In this study the women who 
participated had inevitable abortions defined as an intrauterine gestational sac of less than 45mm with active vaginal 
bleeding.  Participants were excluded if they had anemia, hemodynamic instability, history of clotting disorder or 
were using anticoagulants.  All participants gave their written informed consent and were treated with four 220μg 
tablets (800μg) of Misoprostol (Cytotec) inserted into the posterior formic through a speculum.  For the most part, 
all women returned after three days (range two to five days) for a second 800 μg dose. If the abortion was not 
completed, then vacuum aspiration was offered.
6   
 
 
Results of the study confirmed the majority of patients (84%) treated with Misoprostol were successful in 
the treatment for abortion. Success was defined as the absence of the need for vacuum aspiration for any reason 
within 30 days. There were common side effects reported, such as nausea, vomiting, and abdominal pain. The 
greater part of the participants, an approximate 83%, stated they would recommend this treatment for their family 
and friends. More than three-fourths of the participants (78%) would use Misoprostol again for this treatment. The 
positive outcome of this study showed that the risk of pelvic infection and hemorrhage was very low and side effects 
were tolerable.
6 
 
 Other studies conducted with Misoprostol had similar results. A study in India used a lower dose (400μg 
vaginal Misoprostol) to induce medical evacuation of early pregnancy failure. Though a smaller study with a 
population of only 60 patients, it had similar results; over three-fourths (77%) had a complete abortion. Surprisingly 
70% had completely expelled the fetus with the first dose. The conclusions were that the needs for surgical 
treatments for alternative abortions are more dangerous than Misoprostol treatment.
 31
    
 
Another study conducted in 2005 in the “Clinical Materno Infante of Toluca”, Mexico, determined the 
efficacy of different doses of Misoprostol in an intra-vaginal controlled-release.  The maximum controlled dose of 
100μg produced more rapid vaginal deliveries in a shorter time.  Higher doses did not shorten the time in vaginal 
delivery.
7
 
 
Acceptance among the medical professionals has been significant.  The support in medical literature is 
significant for the positive results of early abortion and the experiences of medical professionals and health 
providers. Cultures that support early abortions but have limited funding may influence providers to adopt this new 
technique.
8
   In Scotland, physicians have utilized regimens that are cost-efficient rather than utilizing hospital 
operating rooms, which typically involves general anesthesia.  The post abortion follow-up visits are crucial to make 
sure that the abortion was complete and that there are no further complications.
8   
  
GLOBAL PERSPECTIVE AND RESEARCH OVERVIEW 
 
 According to available data, induced abortions have seen a decline of four million worldwide between 1995 
and 2003, coming down from 46 million to approximately 42 million. By 2003, there were 26 abortions per 1,000 
women in developed countries in contrast to 29 per 1,000 in developing countries.
9
 A decrease in developing 
countries is observed rather than in developed countries.  A strong market for safe induced abortions worldwide is a 
need especially in parts of Asia, Latin America and Africa. Complications due to unsafe abortion procedures 
account for an estimated 13% of maternal deaths worldwide and it is estimated that millions of women are 
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hospitalized due to complicatons.
10
 Cuba and the Russian Federation have the highest abortion rates of 109% and 
104% percent respectively, indicating that more abortions than births occur annually.
11
 Even though induced 
abortions have fluctuated from country to country, there is still a great need for legal abortions worldwide.  This 
market should be analyzed for there is a great market for a supplier of prostaglandins together with the abortion pill 
RU-486 to successfully terminate pregnancy. In many countries, Misoprostol is used for this procedure.  To increase 
its market share, studies should be focused on the effects of this drug. If Misoprostol is utilized, hospitals and 
community pharmacists would play an important role in collecting reports of adverse drug reactions (ADR’s); for 
this would be the basis of post-marketing surveillance of the drug.  Since millions of women are hospitalized due to 
complications of abortions, hospital pharmacists may serve as a key instrument in the pharmacovigilance of this 
“off-label” drug.  Today the pharmacist also frequently acts as a consultant on pharmacotherapy for both physicians 
and patients even though the fundamental role is to ensure the safety of medicines.
12  
Hospital pharmacists are 
directly involved in patient care and can document and monitor this “off-label” medicine.  On a worldwide scope, 
pharmacists can be instrumental in “off-label” drugs for the pharmacokinetics, pharocodynamic and interactions of 
drugs that can determine the overall effects. 
 
 
Table 1 – Maternal Mortality (WHO, 2000) 
 
 
 
 For the past 20 years, improving maternal health has been an issue on the global agenda. It is estimated that 
500,000 or more women die each year due to complications from pregnancy and childbirths.
 32
 This is more evident 
in developing regions like Africa and Asia, unlike developed regions like Europe and the U.S. as clearly indicated in 
Table 1. 
 
Further research needs to be done on the medical management of Misoprostol for early pregnancy failures. 
The lowest effective dose of Misoprostol for each individual condition is not yet clear since there are different 
categories of pregnancy loss. Doses of the drug may vary for different categories of patients and their different 
conditions. The safety, efficiency and acceptability of this treatment should be studied further. The statistical 
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analysis reported in the New England Journal of Medicine of August 25, 2005, that pregnancy failure treated with 
800 mg of Misoprostol vaginally was a safe approach with 84% high success rate. Future studies conclude the same 
results. Marketing of Misoprostol may be studied for market penetration to countries where the “off-label” drug is 
presently utilized and FDA regulations are none existent. Indirect marketing may then be used not only to focus on 
Misoprostol as an ulcer drug, but by indicating the “off label” effects. One would be indirectly marketing other 
possible uses without breaking any laws. Marketing efforts with worldwide distributors are important due to 
worldwide demand and saving the lives of less fortunate women. The uterotonic and cervical ripening actions it has 
on women and the possibility of treating or preventing post-partum hemorrhage would also influence the market. 
Pharmacokinetics, due to different routes of administration, cause different side effects and acid peaks which slowly 
decline. These side effects are of essence for early termination. Due to lack of studies, there is no specific indication 
on the amount of drug that should be administered. 
 
PHARMACEUTICAL MARKETS 
 
Pharmaceutical companies need to cover many different markets to diminish the high costs of researching 
and developing of drugs. When a drug has “off-label” uses in different countries, it creates a great opportunity for a 
new product, as long as the legal and government restrictions don’t conflict with the drug’s use and expected drug 
results.  Existing drugs compete with new drugs, which may reduce the probability of expected entry acceptance.  
Demographics provide a rough measurement of demand and market size, and a company’s number of drugs 
measures the expertise in that market. 
14 
Canada, Mexico, the Netherlands, and Sweden enact price controls during 
sample periods as reactions to perceived high profits to be earned by pharmaceutical companies.
14  
 
Market regulatory barriers of price regulation are fixed and variable costs must be a concern before 
introducing drugs to the market. Competition of generics and other substitute drugs are available in markets. All this 
diminishes market advertising, but not entirely withdraws it. There is a risk when first introducing new drugs to the 
market, but it soon diminishes.  Those countries that regulate price controls by governments should not discourage 
the introduction of a drug since volume of sales and patient satisfaction will ultimately produce a positive return.  In 
pharmaceutical markets, not only is the cost/benefit relation a concern, but also the worldwide benefit of a drug is of 
great importance.  Misoprostol (Cytotec) is considered a mature product (by its company); therefore, for the past 
couple of years, it has not been marketed for use as ulcer and gastric treatment. Although its “off-label” use as an 
effective abortion pill is utilized worldwide, the pharmaceutical company will not market this drug for fear of 
repercussion of anti-abortion groups and boycotts.  Distributors are utilized for this drug, which may suggest the 
avoidance of price-controlled markets that enable high price for its therapeutic value.
14
At the mature stage of a drug, 
the product sales growth slows down even though, at this point, it lasts longer.  Marketing management of a mature 
drug is important because overcapacity leads to greater competition, especially when a drug competes with 
generics.
15 
At this stage, it is prudent to increase the budget of Research and Development to find different versions 
of the drug, especially when women around the world can benefit from this product.  The use of Cytotec is evolving 
to meet patient’s needs. 
 
ABORTION AND WORLD WIDE MARKETS 
 
When analyzing the worldwide marketing environment, one must consider political/legal, socio/cultural 
and demographic factors, together with the specific need to increase safety in abortions today.  Even though induced 
abortions have declined from approximately 46 million to 42 million, about one in five pregnancies worldwide ends 
in abortion.
16
This is demonstrated more in developed countries where more contraceptives and information is 
available and where abortions are legal and safe.  In developed countries, such as eastern Europe, there are more 
abortions than births; however, developing countries, such as Africa, also have experienced an increase in induced 
abortions.
16
 In Asia and Latin America, a slow decline is reported, probably due to political and legal implications.  
An example of this is the country of El Salvador where abortion is a serious felony for everyone involved.  Women 
may serve up to 30 years in prison and health providers may also serve 6 to 12 years.
17
 In Asia, most abortions occur 
due to the concentrated population. Socio-cultural influences on nations also play a big role.  In South America, a 
very Catholic influence affects the political and legal system.  There is an emphasis to restrict induced abortion laws 
in Latin America in the past years. Only in Cuba and a few other Caribbean nations is abortion legal and safe.  An 
example of this is Uruguay, where the Senate was three votes shy of legalizing abortion, and Argentina’s Congress, 
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in some instances, is considering bills to legalize abortion.
18
 Even though Latin America has strict abortion laws, it 
is developing a high abortion rate in comparison to other nations.  A high mortality rate is demonstrated in these 
areas because there are strict laws which force the abortions to be performed clandestinely. One of the largest 
Catholic countries, Brazil, is pushing for new regulations that permit rape victims to get an abortion without police 
or legal requirements.
18  
 
 Latin Americans do not fully support the legalization of abortions, but many believe abortion should be 
permitted to save a woman’s life if she has been raped or if the fetus will not survive.18 In Brazil, abortion is legal in 
cases of rape or to save the life of the woman. 
 
 It is estimated that 100,000 women in the Philippines have complications due to induced abortions and are 
therefore hospitalized.  Many of these women, when faced with the legal constraints and socio-cultural issue in 
which the country considers abortion a criminal act, must resort to unsafe and clandestine abortions along with the 
negative connotation.
19 
A nation’s socio-cultural influences are the strongest, but one must focus on the health-
related issues for females as a priority.  Worldwide attitudes are slowly changing toward women having successful 
family size goals and good reproductive health.  It may take years, but the shift to focus on women in developing 
countries is slowly growing as those in developed countries or nations that don’t have negative political/legal and 
socio-cultural connotations of induced abortions.  As this happens, potential market for Misoprostol will increase 
and the demand for a safe drug to induce abortions will grow.  Changes in the environment will increase future 
demands that will positively affect the global marketplace.   
 
 The globalization of the world’s economy and the need for safe and effective abortions are great 
opportunities for Misoprostol. Eastern countries, China, and Latin America are future markets.  The pharmaceutical 
manufacturer drug of Misoprostol (Cytotec) should continue to expand its marketing program to foreign countries, 
focusing primarily on nations with political stability, and should slowly increase marketing literature of studies to 
health providers where negative attitudes exist towards safe abortions. 
 
GLOBAL MARKETING: ANALYSIS AND DISCUSSION 
 
Induced abortion and anti-abortion issues are volatile and create great controversies for pharmaceutical 
companies, thus the reason why many want to avoid such topics for personal or political reasons. The analysis of 
expected profit versus the hassles of boycott by anti-abortionists and liabilities is of great concern.  Still, times are 
changing and Misoprostol (Cytotec) represents a great future opportunity.  The increasing demand for safe induced 
abortions is a benefit that adds to consumer satisfaction.  The marketing offer of Misoprostol (Cytotec) to women 
worldwide, especially in nations where abortion is legal, together with governments and organizations, will provide 
a stable market. Then a marketing management of targeting future markets can continue on with a selective 
segmentation.  The drug production concept of “Misoprostol (Cytotec), a safe induced abortion drug,” can be 
implemented together with more affordability than medical interventions as a great alternative.  Even though there is 
a generic version of the drug marketing of Misoprostol (Cytotec), this should increase the selling concept.  
Misoprostol (Cytotec) will have to compete with generics, just like brand name pain killers and other over-the-
counter drugs compete with generics. Considerations of brand recognitions tend to influence the buyer, thus 
assuming the quality is greater than that of it’s competing generics. Not only is the target market women who 
ultimately use the drug, but the physicians that prescribe it.  By focusing on continuously educating the physicians 
and health providers, one creates loyalty and retention of the drug.  Market penetration of Latin America may start in 
Mexico where a study was done in 2005 in which the Clinical Materno Infante of Toluca had positive results.  
Education and clinical studies seem to be the key to developing markets starting with health care providers and 
women political rights supporters.  This will create a relationship of value and more confidence in the drug usage.  A 
managed worldwide marketing effort, commencing with the countries of France, Cuba, and the Russian Federation, 
will create a bridge to satisfy the need in Asia and Africa.  After strengthening existing markets there, an intense 
educational effort may be implemented where the need is greatest.  To measure the results, the control may be in the 
hospitals and/or clinics to continuously evaluate the results of the drug.   Pharmacists may play a key role in 
monitoring and administrating the drug to health care providers, evaluating the response, and playing an active part 
if any corrective action is needed for completion of a successful induced abortion.  The main goal is the safety and 
well-being of women.  The threat of governments that make regulations against women rights should also be a 
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concern. An action program to implement the availability of Misoprostol (Cytotec) should and can be an option, 
especially when the life of a woman is at stake.  Marketing control in hostile environments may present a challenge, 
for instance in China where millions of abortions take place annually, as legal restrictions do not affect its incidence 
and the Chinese will not be targeted by anti-abortionists under their laws. Cambodia can be a gateway to all Asian 
nations since in the past ten years, they have liberalized their laws concerning safe abortions. 
 
LIFE-CYCLE OF THE DRUG 
 
When a drug reaches the maturity stage, usually the product’s growth rate slows down, even though this 
stage is a longer one. Cytotec has stable distribution channels due its “off-label” use.  The growth of sales is relevant 
to demand by growth of population and replacement demand. Cytotec was intended for NSAID-induced ulcers; 
today substitute drugs have reduced the product’s use for this purpose. While there is the overcapacity of 
competitors in some countries, marketing personnel must ignore the low success rate of the intended product and 
must be concerned with the new “off-label” use of this drug. Worldwide successful research, where abortions are 
legal and necessary to save women’s lives, is the new market segment. Maintaining the company’s investment and 
production level until the uncertainties of the product are resolved is prudent.
 20
 
 
MANAGEMENT IMPLICATIONS  
 
A relationship marketing strategy that focuses on keeping and improving customers is one that assumes 
loyalty and an on-going relationship in search of greater value.
 22
 Misoprostol (Cytotec) has had a long-term 
relationship with the pharmaceutical market, which is why the price is typically low. Since there is no advertising 
nor promotion, research for new and more reliable ways to improve the product’s safety for its “off-label” use 
should be a consideration. Need recognition and research information affect the consumer decision process of 
evaluating all the alternatives available to them. Beliefs and expectations, along with attitudes and intentions, 
influence the actual behavior of consumers. Ultimately, product quality, situational factors, and personal 
characteristics will all be linked toward customer satisfaction and the perceived value of treatments. Patient 
feedback is the essential key to prolong the maturity stage of a product. 
 
Demographic variables and psychographic concerns must also play a key role for every country has its own 
segmentated behavior influenced by cultural, religious and political concerns. The ultimate goal of saving women 
worldwide must be the priority. Research pharmacists must continue to study the pharmacological aspects, thus 
achieving a drug that is superior to its predecessors. Diffusion of information is key for scholars to research and find 
solutions for situations that may arise. 
 
SUMMARY 
 
Misoprostol (Cytotec) presents a future challenge to pharmaceutical companies for marketing and 
supplying the worldwide need for induced abortions. This drug provides a safe, effective and affordable way in 
which abortion could and should be approached. Clinical research supports the advantages of Misoprostol as an 
abortion drug and the acceptability of the treatment. It is the role of modern pharmacy and its branches, such as 
Pharmacodynamics and Pharmacokinetics research, which could provide the ideal results to confirm the clinical 
studies. 
 
The following course of action should be considered:  those countries where Misoprostol is approved for 
ob/gyn indications could serve as a marketing launch point to countries where the drug is approved, but have no 
indication for the approval of abortion. After these locations are marketed, then those countries where the drug is not 
approved may follow. Times are changing rapidly, and so is the pharmaceutical industry. It is just a matter of time 
until Misoprostol is approved worldwide for women in need of abortion. 
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